EP1613961A4 - Surface receptor complexes as biomarkers - Google Patents

Surface receptor complexes as biomarkers

Info

Publication number
EP1613961A4
EP1613961A4 EP04759065A EP04759065A EP1613961A4 EP 1613961 A4 EP1613961 A4 EP 1613961A4 EP 04759065 A EP04759065 A EP 04759065A EP 04759065 A EP04759065 A EP 04759065A EP 1613961 A4 EP1613961 A4 EP 1613961A4
Authority
EP
European Patent Office
Prior art keywords
biomarkers
surface receptor
receptor complexes
complexes
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04759065A
Other languages
German (de)
French (fr)
Other versions
EP1613961A2 (en
Inventor
Po-Ying Chan-Hui
Hossein Salimi-Moosavi
Yining Shi
Sharat Singh
Rajiv Dua
Ali Mukherjee
Sailaja Pidaparthi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Monogram Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/623,057 external-priority patent/US7105308B2/en
Application filed by Monogram Biosciences Inc filed Critical Monogram Biosciences Inc
Publication of EP1613961A2 publication Critical patent/EP1613961A2/en
Publication of EP1613961A4 publication Critical patent/EP1613961A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP04759065A 2003-04-01 2004-03-30 Surface receptor complexes as biomarkers Withdrawn EP1613961A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US45988803P 2003-04-01 2003-04-01
US10/623,057 US7105308B2 (en) 2002-07-25 2003-07-17 Detecting receptor oligomerization
US49448203P 2003-08-11 2003-08-11
US50803403P 2003-10-01 2003-10-01
US51294103P 2003-10-20 2003-10-20
US52325803P 2003-11-18 2003-11-18
PCT/US2004/009717 WO2004092353A2 (en) 2003-04-01 2004-03-30 Surface receptor complexes as biomarkers

Publications (2)

Publication Number Publication Date
EP1613961A2 EP1613961A2 (en) 2006-01-11
EP1613961A4 true EP1613961A4 (en) 2007-03-07

Family

ID=33136354

Family Applications (3)

Application Number Title Priority Date Filing Date
EP20040758577 Withdrawn EP1613732A4 (en) 2003-04-01 2004-03-30 Intracellular complexes as biomarkers
EP04759065A Withdrawn EP1613961A4 (en) 2003-04-01 2004-03-30 Surface receptor complexes as biomarkers
EP04759064.1A Expired - Lifetime EP1613205B1 (en) 2003-04-01 2004-03-30 Erbb surface receptor complexes as biomarkers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP20040758577 Withdrawn EP1613732A4 (en) 2003-04-01 2004-03-30 Intracellular complexes as biomarkers

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP04759064.1A Expired - Lifetime EP1613205B1 (en) 2003-04-01 2004-03-30 Erbb surface receptor complexes as biomarkers

Country Status (6)

Country Link
EP (3) EP1613732A4 (en)
JP (2) JP2006521821A (en)
AU (3) AU2004229348A1 (en)
BR (3) BRPI0408928A (en)
CA (3) CA2521082A1 (en)
WO (3) WO2004087887A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
CA2521082A1 (en) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Surface receptor complexes as biomarkers
WO2005019470A2 (en) 2003-08-11 2005-03-03 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
EP1681983A4 (en) * 2003-10-14 2008-12-10 Monogram Biosciences Inc Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
JP2008513032A (en) * 2004-09-22 2008-05-01 トリパス イメージング， インコーポレイテッド Methods and compositions for assessing the prognosis of breast cancer
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
JP5025724B2 (en) * 2006-04-18 2012-09-12 ウェルスタット バイオロジクス コーポレイション Protein detection from circulating neoplastic cells
CA2663595A1 (en) * 2006-08-07 2008-02-14 The Board Of Regents Of The University Of Texas System Proteomic patterns of cancer prognostic and predictive signatures
BRPI0717416A2 (en) 2006-09-21 2013-11-12 Prometheus Lab Inc METHOD FOR PERFORMING A HIGH PRODUCTIVITY COMPLEX IMMUNOASON, AND
US9250243B2 (en) * 2006-09-21 2016-02-02 Nestec S.A. Drug selection for lung cancer therapy using antibody-based arrays
EP2097754B2 (en) 2006-11-28 2018-01-24 Daiichi Sankyo Europe GmbH Activated her3 as a marker for predicting therapeutic efficacy
PL2129396T3 (en) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings Her-2 diagnostic methods
WO2009108637A1 (en) 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays
EP2304047A4 (en) * 2008-05-07 2012-12-26 Eutropics Pharmaceuticals Inc Antibodies specific to heterodimers of bcl-2 family and uses thereof
BRPI0917871A2 (en) * 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc anti-erbb3 therapeutic agent for use in tumor therapy, methods for predicting tumor responsiveness of an anti-erbb3 therapeutic agent, for selecting anti-erbb3 therapy for a patient, for predicting cell response to treatment with a therapeutic agent , to identify a biomarker, and to prevent administration of an anti-erbb3 cancer drug, and kit to predict cell response to treatment with a therapeutic agent
CA2764386C (en) 2008-12-01 2018-05-01 Laboratory Corporation Of America Holdings P95-her2 antibodies and uses thereof
US8349574B2 (en) 2009-01-15 2013-01-08 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of Her-3
SG172984A1 (en) * 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-2 expression
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
CA2756493C (en) * 2009-03-24 2019-07-02 Biocept, Inc. Devices and methods of cell capture and analysis
NZ596468A (en) 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
JP5931736B2 (en) 2009-11-13 2016-06-08 ウー３・フアルマ・ゲー・エム・ベー・ハーＵ３ Ｐｈａｒｍａ Substances and methods for treating or preventing HER-3-related diseases
EP2859893A1 (en) 2010-03-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
WO2012135695A2 (en) * 2011-03-30 2012-10-04 The Uab Research Foundation Modulation of cellular migration
KR101851425B1 (en) * 2011-09-02 2018-04-23 네스텍 소시에테아노님 Profiling of signal pathway proteins to determine therapeutic efficacy
US20150150869A1 (en) 2012-06-20 2015-06-04 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
CA2908515A1 (en) * 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
KR20160009070A (en) * 2013-05-21 2016-01-25 네스텍 소시에테아노님 Methods for predicting and improving the survival of colorectal cancer patients
WO2015017788A1 (en) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
EP3063302B1 (en) 2013-10-30 2019-12-04 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
KR20170126867A (en) 2015-01-12 2017-11-20 유트로픽스 파마슈티컬스, 인크. Context-dependent diagnostic test to guide cancer treatment
WO2016127220A1 (en) * 2015-02-13 2016-08-18 The University Of Queensland Methods for classifying tumors and uses therefor
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN108780089B (en) 2016-03-15 2020-09-08 美国控股实验室公司 Method for evaluating protein interactions between cells
EP3715844A4 (en) * 2017-11-20 2021-04-14 Konica Minolta, Inc. Drug evaluation method
IT201800008274A1 (en) * 2018-08-31 2020-03-02 Alifax Srl IMMUNOMETRIC METHOD FOR BIOLOGICAL CLINICAL ANALYSIS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024205A1 (en) * 1994-03-07 1995-09-14 New York University Medical Center Methods and compositions for treatment of breast cancer
WO2001083502A1 (en) * 2000-04-28 2001-11-08 Aclara Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
WO2004008099A2 (en) * 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2004011900A2 (en) * 2002-07-25 2004-02-05 Aclara Biosciences, Inc. Detecting receptor oligomerization
WO2004091384A2 (en) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Erbb surface receptor complexes as biomarkers

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5597531A (en) 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
WO1994003812A1 (en) 1992-07-31 1994-02-17 Syntex (U.S.A.) Inc. Photoactivatable chemiluminescent matrices
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5693271A (en) 1994-09-01 1997-12-02 Chase Industries, Inc. Rotationally molding an insulated plastic molded door with integral hinge
US5599631A (en) 1995-03-08 1997-02-04 Eastman Kodak Company Fluorinated elastomer/fluorinated resin compositions for toner fusing members
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6095661A (en) 1998-03-19 2000-08-01 Ppt Vision, Inc. Method and apparatus for an L.E.D. flashlight
US6316603B1 (en) * 1998-09-08 2001-11-13 Agouron Pharmaceuticals, Inc. Modifications of the VEGF receptor-2 protein and methods of use
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6673550B2 (en) 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US6346384B1 (en) 2000-03-27 2002-02-12 Dade Behring Inc. Real-time monitoring of PCR using LOCI
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
JP4796259B2 (en) 2000-05-04 2011-10-19 シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー Composition for use in the detection of multiple analytes
US6547654B2 (en) 2000-07-22 2003-04-15 Americo Del Raso Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander
WO2002068668A2 (en) * 2001-02-22 2002-09-06 Immunex Corporation Compositions and methods for production cell culture
WO2002095356A2 (en) 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
WO2003006947A2 (en) 2001-07-09 2003-01-23 Aclara Biosciences, Inc. Cell-screening assay and composition
CA2354690A1 (en) 2001-07-20 2001-10-27 Jan Prinzmetal Mat
US6545102B1 (en) * 2001-09-27 2003-04-08 Lumigen, Inc. Polymer-supported photosensitizers
WO2003068808A1 (en) * 2002-02-13 2003-08-21 Garvan Institute Of Medical Research Novel protein complexes and uses therefor
JP4694786B2 (en) * 2002-03-01 2011-06-08 ロジャー・ウィリアムズ・ホスピタル Methods and compositions related to the Shc protein for the prediction of breast, prostate and ovarian cancer
AU2003222253A1 (en) * 2002-03-05 2003-09-22 Monogram Biosciences, Inc. Multiplex analysis using membrane-bound sensitizers
EP1681983A4 (en) * 2003-10-14 2008-12-10 Monogram Biosciences Inc Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024205A1 (en) * 1994-03-07 1995-09-14 New York University Medical Center Methods and compositions for treatment of breast cancer
US6630318B1 (en) * 1994-03-07 2003-10-07 New York University Prognostic evaluation of cancer
WO2001083502A1 (en) * 2000-04-28 2001-11-08 Aclara Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
WO2004008099A2 (en) * 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2004011900A2 (en) * 2002-07-25 2004-02-05 Aclara Biosciences, Inc. Detecting receptor oligomerization
WO2004091384A2 (en) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Erbb surface receptor complexes as biomarkers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHAN-HUI P -Y ET AL: "Applications of eTag(TM) assay platform to systems biology approaches in molecular oncology and toxicology studies", CLINICAL IMMUNOLOGY (ORLANDO), vol. 111, no. 2, May 2004 (2004-05-01), pages 162 - 174, XP002404810, ISSN: 1521-6616 *

Also Published As

Publication number Publication date
EP1613732A4 (en) 2012-03-14
BRPI0408961A (en) 2006-10-31
WO2004091384A2 (en) 2004-10-28
AU2004225439A1 (en) 2004-10-14
CA2521106A1 (en) 2004-10-14
WO2004091384A3 (en) 2005-12-29
WO2004087887A2 (en) 2004-10-14
JP2006521821A (en) 2006-09-28
AU2004230700A1 (en) 2004-10-28
BRPI0408950A (en) 2006-03-28
EP1613732A2 (en) 2006-01-11
AU2004229348A1 (en) 2004-10-28
WO2004092353A2 (en) 2004-10-28
WO2004087887A3 (en) 2006-06-15
JP2006523314A (en) 2006-10-12
EP1613961A2 (en) 2006-01-11
WO2004092353A3 (en) 2005-03-03
CA2521077A1 (en) 2004-10-28
BRPI0408928A (en) 2006-09-12
EP1613205A2 (en) 2006-01-11
CA2521082A1 (en) 2004-10-28
EP1613205A4 (en) 2006-11-29
EP1613205B1 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
EP1613961A4 (en) Surface receptor complexes as biomarkers
EP1738870A4 (en) Polisher
EP1737831A4 (en) Neurologically-active compounds
GB2398125B (en) Ruler
GB2412734B (en) Fluid-quantity gauging
EP1755617A4 (en) Perfluorocarbon-soluble compounds
ZA200607162B (en) Profiling surface
AU305435S (en) Planer
GB2418974B (en) Machine-human interface
GB2436246A8 (en) Surface pairs
GB0401269D0 (en) Compounds
GB0414998D0 (en) Monodonor ligands
AU156895S (en) Planer
GB0427063D0 (en) Surface covering
GB0403595D0 (en) Compounds
AU300824S (en) Sander
GB0427405D0 (en) Novel compounds III
AU2003904848A0 (en) Receptor specific ligands
GB0410325D0 (en) Improved ruler
GB0402416D0 (en) Ligands
GB0418568D0 (en) Ligands
GB0403014D0 (en) Ligands
HU2798U (en) Multi purpose device-kit
AU300993S (en) Sanding block
AU2004905087A0 (en) Receptor specific ligands

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051026

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/53 20060101ALI20061102BHEP

Ipc: G01N 33/574 20060101AFI20061102BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091001